

Audit Review Table					
Molina Healthcare of New Mexico (Org ID: 955, Sub ID: 16749, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)					
Measurement Year - 2024; Date & Timestamp - 6/9/2025 5:51:13 PM					
This submission is on the stage: Submission Finalized					
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment
Effectiveness of Care					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)					
BMI percentile (Total)		100.00%	NA	R	Reported
Counseling for Nutrition (Total)		0.00%	NA	R	Reported
Counseling for Physical Activity (Total)		0.00%	NA	R	Reported
Childhood Immunization Status (CIS)					
DTaP			NA	R	Reported
IPV			NA	R	Reported
MMR			NA	R	Reported
HiB			NA	R	Reported
Hepatitis B			NA	R	Reported
VZV			NA	R	Reported
Pneumococcal Conjugate			NA	R	Reported
Hepatitis A			NA	R	Reported
Rotavirus			NA	R	Reported
Influenza			NA	R	Reported
Combo 3			NA	R	Reported
Combo 7			NA	R	Reported
Combo 10			NA	R	Reported
Immunizations for Adolescents (IMA)					
Meningococcal			NA	R	Reported
Tdap			NA	R	Reported
HPV			NA	R	Reported
Combination 1			NA	R	Reported
Combination 2			NA	R	Reported
Lead Screening in Children (LSC)					
Lead Screening in Children			NA	R	Reported
Cervical Cancer Screening (CCS)					
Cervical Cancer Screening		54.55%	NA	R	Reported
Chlamydia Screening in Women (CHL)					
(Total)			NA	R	Reported
Oral Evaluation, Dental Services (OED)	Y				
(0-2)		18.86%	R	R	Reported
(3-5)		38.45%	R	R	Reported
(6-14)		40.82%	R	R	Reported
(15-20)		25.33%	R	R	Reported
(Total)		33.11%	R	R	Reported
Topical Fluoride for Children (TFC)					
(1-2)		0.00%	NA	R	Reported
(3-4)			NA	R	Reported
(Total)		0.00%	NA	R	Reported
Appropriate Testing for Pharyngitis (CWP)	Y				
(Total)			NA	R	Reported
Pharmacotherapy Management of COPD Exacerbation (PCE)	Y				
Systemic Corticosteroid		76.92%	NA	R	Reported
Bronchodilator		69.23%	NA	R	Reported
Asthma Medication Ratio (AMR)	Y				
(Total)			NA	R	Reported
Controlling High Blood Pressure (CBP)					
Controlling High Blood Pressure		80.00%	NA	R	Reported
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	Y				
Persistence of Beta-Blocker Treatment After a Heart Attack			NA	R	Reported
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Y				
Received Statin Therapy (Total)			NA	R	Reported
Statin Adherence 80% (Total)			NA	R	Reported
Cardiac Rehabilitation (CRE)					
Initiation (Total)			NA	R	Reported

Engagement1 (Total)			NA	R	Reported
Engagement2 (Total)			NA	R	Reported
Achievement (Total)			NA	R	Reported
Glycemic Status Assessment for Patients With Diabetes (GSD)					
Glycemic Status <8.0%		100.00%	NA	R	Reported
Glycemic Status >9.0%		0.00%	NA	R	Reported
Blood Pressure Control for Patients With Diabetes (BPD)					
Blood Pressure Control for Patients With Diabetes		60.00%	NA	R	Reported
Eye Exam for Patients With Diabetes (EED)					
Eye Exam for Patients With Diabetes		20.00%	NA	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
(Total)		60.00%	NA	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Received Statin Therapy		100.00%	NA	R	Reported
Statin Adherence 80%		66.67%	NA	R	Reported
Diagnosed Mental Health Disorders (DMH)					
(Total)		16.00%	NA	R	Reported
Antidepressant Medication Management (AMM)	Y				
Effective Acute Phase Treatment			NA	R	Reported
Effective Continuation Phase Treatment			NA	R	Reported
Follow-Up After Hospitalization for Mental Illness (FUH)	Y				
30 days (Total)		47.67%	R	R	Reported
7 days (Total)		29.07%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	Y				
30 days (Total)		35.96%	R	R	Reported
7 days (Total)		15.73%	R	R	Reported
Diagnosed Substance Use Disorders (DSU)					
Alcohol (Total)		0.00%	NA	R	Reported
Opioid (Total)		0.00%	NA	R	Reported
Other (Total)		0.00%	NA	R	Reported
Any (Total)		0.00%	NA	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Y				
30 days (Total)		34.67%	R	R	Reported
7 Days (Total)		17.33%	R	R	Reported
Follow-Up After Emergency Department Visit for Substance Use (FUA)	Y				
30 days (Total)		34.97%	R	R	Reported
7 days (Total)		24.59%	R	R	Reported
Pharmacotherapy for Opioid Use Disorder (POD)	Y				
(Total)			NA	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications			NA	R	Reported
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia			NA	R	Reported
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)					
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia			NA	R	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia			NA	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Y				
(Total)			NA	R	Reported
Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)	Y				
(Total)			NA	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
(Total)			NA	R	Reported
Use of Opioids at High Dosage (HDO)	Y				
Use of Opioids at High Dosage		0.00%	NA	R	Reported

Use of Opioids From Multiple Providers (UOP)	Y				
<i>Multiple Prescribers</i>		0.00%	NA	R	Reported
<i>Multiple Pharmacies</i>		0.00%	NA	R	Reported
<i>Multiple Prescribers and Multiple Pharmacies</i>		0.00%	NA	R	Reported
Risk of Continued Opioid Use (COU)	Y				
<i>>=15 Days (Total)</i>		0.00%	NA	R	Reported
<i>>=31 Days (Total)</i>		0.00%	NA	R	Reported
Access/Availability of Care					
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
<i>(Total)</i>		100.00%	NA	R	Reported
Initiation and Engagement of Substance Use Disorder Treatment (IET)	Y				
<i>Initiation of SUD Treatment - Total (Total)</i>			NA	R	Reported
<i>Engagement of SUD Treatment - Total (Total)</i>			NA	R	Reported
Prenatal and Postpartum Care (PPC)					
<i>Timeliness of Prenatal Care</i>		91.94%	R	R	Reported
<i>Postpartum Care</i>		62.90%	R	R	Reported
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	Y				
<i>(Total)</i>		33.33%	NA	R	Reported
Utilization and Risk Adjusted Utilization					
Well-Child Visits in the First 30 Months of Life (W30)					
<i>(First 15 Months)</i>			NA	R	Reported
<i>(15 Months-30 Months)</i>			NA	R	Reported
Child and Adolescent Well-Care Visits (WCV)					
<i>(Total)</i>		0.00%	NA	R	Reported
Antibiotic Utilization for Respiratory Conditions (AXR)	Y				
<i>(Total)</i>			NA	R	Reported
Plan All-Cause Readmissions (PCR)			R	R	Reported
Health Plan Descriptive Information					
Enrollment by Product Line (ENP)			R	R	Reported
Language Diversity of Membership (LDM)			R	R	Reported
Race/Ethnicity Diversity of Membership (RDM)			R	R	Reported
Measures Reported Using Electronic Clinical Data Systems					
Childhood Immunization Status (CIS-E)					
<i>DTaP</i>			NA	R	Reported
<i>IPV</i>			NA	R	Reported
<i>MMR</i>			NA	R	Reported
<i>Hib</i>			NA	R	Reported
<i>Hepatitis B</i>			NA	R	Reported
<i>VZV</i>			NA	R	Reported
<i>Pneumococcal Conjugate</i>			NA	R	Reported
<i>Hepatitis A</i>			NA	R	Reported
<i>Rotavirus</i>			NA	R	Reported
<i>Influenza</i>			NA	R	Reported
<i>Combo 3</i>			NA	R	Reported
<i>Combo 7</i>			NA	R	Reported
<i>Combo 10</i>			NA	R	Reported
Immunizations for Adolescents (IMA-E)					
<i>Meningococcal</i>			NA	R	Reported
<i>Tdap</i>			NA	R	Reported
<i>HPV</i>			NA	R	Reported
<i>Combination 1</i>			NA	R	Reported
<i>Combination 2</i>			NA	R	Reported
Breast Cancer Screening (BCS-E)					
<i>Breast Cancer Screening</i>		66.67%	NA	R	Reported
Cervical Cancer Screening (CCS-E)					
<i>Cervical Cancer Screening</i>		54.55%	NA	R	Reported
Colorectal Cancer Screening (COL-E)					
<i>(Total)</i>		77.78%	NA	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)	Y				
<i>Initiation Phase</i>			NA	R	Reported
<i>Continuation and Maintenance Phase</i>			NA	R	Reported

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)	Y				
<i>Blood Glucose Testing (Total)</i>			NA	R	Reported
<i>Cholesterol Testing (Total)</i>			NA	R	Reported
<i>Blood Glucose and Cholesterol Testing (Total)</i>			NA	R	Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)					
<i>Depression Screening (Total)</i>		9.09%	NA	R	Reported
<i>Follow-Up on Positive Screen (Total)</i>			NA	R	Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E)					
<i>Utilization of PHQ-9-Total (Total)</i>		0.00%	NA	R	Reported
Depression Remission or Response for Adolescents and Adults (DRR-E)					
<i>Follow-Up PHQ-9 (Total)</i>			NA	R	Reported
<i>Depression Remission (Total)</i>			NA	R	Reported
<i>Depression Response (Total)</i>			NA	R	Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E)					
<i>Unhealthy Alcohol Use Screening (Total)</i>		0.00%	NA	R	Reported
<i>Alcohol Counseling or Other Follow-Up Care (Total)</i>			NA	R	Reported
Adult Immunization Status (AIS-E)					
<i>Influenza (Total)</i>		36.84%	NA	R	Reported
<i>Td/Tdap (Total)</i>		47.37%	NA	R	Reported
<i>Zoster (Total)</i>		31.25%	NA	R	Reported
<i>Pneumococcal (66+)</i>			NA	R	Reported
Prenatal Immunization Status (PRS-E)					
<i>Influenza</i>		22.45%	R	R	Reported
<i>Tdap</i>		52.38%	R	R	Reported
<i>Combination</i>		17.01%	R	R	Reported
Prenatal Depression Screening and Follow-Up (PND-E)					
<i>Depression Screening</i>		0.00%	R	R	Reported
<i>Follow-Up on Positive Screen</i>			NA	R	Reported
Postpartum Depression Screening and Follow-Up (PDS-E)					
<i>Depression Screening</i>		0.00%	R	R	Reported
<i>Follow-Up on Positive Screen</i>			NA	R	Reported
Social Need Screening and Intervention (SNS-E)					
<i>Food Screening (Total)</i>		0.00%	NA	R	Reported
<i>Food Intervention (Total)</i>			NA	R	Reported
<i>Housing Screening (Total)</i>		0.00%	NA	R	Reported
<i>Housing Intervention (Total)</i>			NA	R	Reported
<i>Transportation Screening (Total)</i>		0.00%	NA	R	Reported
<i>Transportation Intervention (Total)</i>			NA	R	Reported